Table 4 Treatment response
ERKD treatment response | Post ERKD treatment | ||||
|---|---|---|---|---|---|
Pt. no. | ERKD monotherapy or multimodality treatment | CR, PR, Stable | Duration of response | Modality | Response |
1 | ERKD Mono-TX | Progression |  | Avastin | Clinical neurological deterioration, ↑blindness |
2 | ERKD Mono-TX | Stable at 6 weeks; progression at 12 weeks | 6 weeks | Decadron | Â |
3 | Mono-TX | Stable | 5 years remission | None | Remission 5 years. Good quality of life |
4 | Multi modal with Chemo-TX | Stable ? | 4 years remission | Chemo-TX | 4 years remission good quality of life |
5 | Multi modal Rad-TX and TMZ | CR | 4 months | CPT-11 Bevacizumab | Â |
6 | ERKD and Vinblastine | Stable | >12 months | Â | Â |
7 | ERKD and Avastin | Stable | 4 months | Decadron | Â |